Pad  Chivukula net worth and biography

Pad Chivukula Biography and Net Worth

Dr. Pad Chivukula is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.

What is Pad Chivukula's net worth?

The estimated net worth of Pad Chivukula is at least $6.85 million as of October 15th, 2024. Dr. Chivukula owns 435,334 shares of Arcturus Therapeutics stock worth more than $6,847,804 as of December 18th. This net worth approximation does not reflect any other assets that Dr. Chivukula may own. Additionally, Dr. Chivukula receives an annual salary of $687,500.00 as COO at Arcturus Therapeutics. Learn More about Pad Chivukula's net worth.

How old is Pad Chivukula?

Dr. Chivukula is currently 45 years old. There are 3 older executives and no younger executives at Arcturus Therapeutics. The oldest executive at Arcturus Therapeutics is Dr. Juergen Froehlich FCPh, M.D., MBA, Chief Medical Officer, who is 68 years old. Learn More on Pad Chivukula's age.

What is Pad Chivukula's salary?

As the COO of Arcturus Therapeutics Holdings Inc., Dr. Chivukula earns $687,500.00 per year. The highest earning executive at Arcturus Therapeutics is Mr. Joseph E. Payne M.Sc., Founder, President, CEO & Director, who commands a salary of $906,500.00 per year. Learn More on Pad Chivukula's salary.

How do I contact Pad Chivukula?

The corporate mailing address for Dr. Chivukula and other Arcturus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. Arcturus Therapeutics can also be reached via phone at (858) 900-2660 and via email at [email protected]. Learn More on Pad Chivukula's contact information.

Has Pad Chivukula been buying or selling shares of Arcturus Therapeutics?

Over the course of the past ninety days, Pad Chivukula has sold $249,120.00 in shares of Arcturus Therapeutics stock. Most recently, Pad Chivukula sold 12,000 shares of the business's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a transaction totalling $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares of the company's stock, valued at $9,037,533.84. Learn More on Pad Chivukula's trading history.

Are insiders buying or selling shares of Arcturus Therapeutics?

During the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 64,114 shares worth more than $2,204,944.35. The most recent insider tranaction occured on October, 15th when COO Pad Chivukula sold 12,000 shares worth more than $249,120.00. Insiders at Arcturus Therapeutics own 15.3% of the company. Learn More about insider trades at Arcturus Therapeutics.

Information on this page was last updated on 10/15/2024.

Pad Chivukula Insider Trading History at Arcturus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/15/2024Sell12,000$20.76$249,120.00435,334View SEC Filing Icon  
6/5/2024Sell114$45.00$5,130.00447,334View SEC Filing Icon  
6/3/2024Sell26,000$40.01$1,040,260.00447,448View SEC Filing Icon  
3/25/2024Sell17,435$35.02$610,573.70473,448View SEC Filing Icon  
3/19/2024Sell8,565$35.01$299,860.65490,883View SEC Filing Icon  
11/1/2023Sell5,000$18.72$93,600.00499,448View SEC Filing Icon  
10/2/2023Sell5,000$25.61$128,050.00504,448View SEC Filing Icon  
9/1/2023Sell5,000$31.45$157,250.00509,448View SEC Filing Icon  
7/14/2023Sell25,000$35.01$875,250.00519,448View SEC Filing Icon  
7/3/2023Sell5,000$28.75$143,750.00544,448View SEC Filing Icon  
5/10/2023Sell17,075$30.00$512,250.00562,373View SEC Filing Icon  
5/1/2023Sell5,000$25.93$129,650.00579,448View SEC Filing Icon  
4/3/2023Sell5,000$25.38$126,900.00584,448View SEC Filing Icon  
3/6/2023Sell5,000$16.07$80,350.00589,448View SEC Filing Icon  
1/4/2022Sell8,100$40.00$324,000.00View SEC Filing Icon  
12/16/2021Sell3,633$40.00$145,320.00View SEC Filing Icon  
12/8/2021Sell6,367$40.00$254,680.00View SEC Filing Icon  
11/1/2021Sell10,000$44.41$444,100.00View SEC Filing Icon  
10/1/2021Sell10,000$44.36$443,600.00View SEC Filing Icon  
9/1/2021Sell10,000$55.86$558,600.00View SEC Filing Icon  
8/3/2021Sell10,000$40.07$400,700.00View SEC Filing Icon  
1/4/2021Sell10,000$46.40$464,000.00
11/2/2020Sell10,000$55.28$552,800.00View SEC Filing Icon  
10/1/2020Sell10,000$42.83$428,300.00View SEC Filing Icon  
9/3/2020Sell10,000$45.16$451,600.00View SEC Filing Icon  
See Full Table

Pad Chivukula Buying and Selling Activity at Arcturus Therapeutics

This chart shows Pad Chivukula's buying and selling at Arcturus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arcturus Therapeutics Company Overview

Arcturus Therapeutics logo
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $15.67
Low: $15.33
High: $16.13

50 Day Range

MA: $18.62
Low: $15.73
High: $21.89

2 Week Range

Now: $15.67
Low: $14.93
High: $45.00

Volume

148,096 shs

Average Volume

464,373 shs

Market Capitalization

$424.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.62